Niflumic acid
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 457481224 | IUPAC_name = 2-{[3-(trifluoromethyl)phenyl]amino}nicotinic acid | image = Niflumic acid.png
| tradename = | Drugs.com = International Drug Names | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =
| bioavailability = | protein_bound = | metabolism = | elimination_half-life = 2.5 hr[1] | excretion =
| CASNo_Ref = 
| CAS_number_Ref = 
| CAS_number = 4394-00-7
| ATC_prefix = M01
| ATC_suffix = AX02
| ATC_supplemental = M02AA17 (WHO)
| IUPHAR_ligand = 2439
| DrugBank_Ref =
| DrugBank =
| ChEMBL_Ref =
| ChEMBL = 63323
| UNII_Ref =
| UNII = 4U5MP5IUD8
| KEGG_Ref =
| KEGG = D08275
| PubChem = 4488
| ChemSpiderID_Ref =
| ChemSpiderID = 4333
| smiles = C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F
| InChI = 1/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)
| InChIKey = JZFPYUNJRRFVQU-UHFFFAOYAR
| StdInChI_Ref =
| StdInChI = 1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)
| StdInChIKey_Ref =
| StdInChIKey = JZFPYUNJRRFVQU-UHFFFAOYSA-N
| C=13 | H=9 | F=3 | N=2 | O=2 | molecular_weight = 282.21797 g/mol }}
|
WikiDoc Resources for Niflumic acid |
|
Articles |
|---|
|
Most recent articles on Niflumic acid Most cited articles on Niflumic acid |
|
Media |
|
Powerpoint slides on Niflumic acid |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Niflumic acid at Clinical Trials.gov Trial results on Niflumic acid Clinical Trials on Niflumic acid at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Niflumic acid NICE Guidance on Niflumic acid
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Niflumic acid Discussion groups on Niflumic acid Patient Handouts on Niflumic acid Directions to Hospitals Treating Niflumic acid Risk calculators and risk factors for Niflumic acid
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Niflumic acid |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Niflumic acid is a drug used for joint and muscular pain. It is categorized as an inhibitor of cyclooxygenase-2. In experimental biology, it has been employed to inhibit chloride channels.[2] It has also been reported to act on GABA-A[3] and NMDA channels[4] and to block T-type calcium channels.[5]
References
- ↑ "Half life". Drug Bank. Retrieved 15 July 2011.
- ↑ Knauf, Philip A.; Mann, Nancy A (1984). "Use of niflumic acid to determine the nature of the asymmetry of the human erythrocyte anion exchange system". J. Gen. Physiol. 83: 703–725. doi:10.1085/jgp.83.5.703. PMC 2215658. PMID 6736917.
- ↑ Sinkkonen ST et al. (2003): Receptor subtype-dependent positive and negative modulation of GABA(A) receptor function by niflumic acid, a nonsteroidal anti-inflammatory drug, Mol Pharmacol, p. 753-63. PMID 12920213
- ↑ Lerma J., Martin d.R. (1992). "Chloride transport blockers prevent N-methyl-D-aspartate receptor-channel complex activation". Mol. Pharmacol. 41 (2): 217–222. PMID 1371581.
- ↑ Balderas E et al. (2012): Niflumic acid blocks native and recombinant T-type channels, J Cell Physiol, p. 2542-55. PMID 21898399
- Template:drugs.com link with non-standard subpage
- Articles with changed CASNo identifier
- Chembox and Drugbox articles with a broken CheMoBot template
- Articles with changed EBI identifier
- Articles with changed FDA identifier
- Articles with changed ChemSpider identifier
- Articles with changed InChI identifier
- Nicotinic acids
- Anilines
- Organofluorides
- Calcium channel blockers
- GABAA receptor positive allosteric modulators
- NMDA receptor antagonists
- Drug